HC Wainwright Reaffirms Buy Rating for Pharming Group (NASDAQ:PHAR)

HC Wainwright reissued their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a report issued on Thursday morning, Benzinga reports. HC Wainwright currently has a $37.00 target price on the stock.

Pharming Group Trading Up 4.8 %

Shares of Pharming Group stock opened at $8.70 on Thursday. The firm has a market capitalization of $585.89 million, a price-to-earnings ratio of -54.38 and a beta of 0.15. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $13.20. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. The stock has a 50 day moving average of $8.05 and a 200 day moving average of $8.53.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The business had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. During the same quarter in the previous year, the company posted $0.02 earnings per share. As a group, research analysts predict that Pharming Group will post -0.15 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in Pharming Group (NASDAQ:PHAR) by 75.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.